Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease
- 作者: Goncharov A.1, Sasunova A.1, Pilipenko V.1, Isakov V.1
-
隶属关系:
- Federal Research Center of Nutrition, Biotechnology and Food Safety
- 期: 卷 95, 编号 8 (2023)
- 页面: 641-647
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/148308
- DOI: https://doi.org/10.26442/00403660.2023.08.202348
- ID: 148308
如何引用文章
全文:
详细
Aim. To evaluate the efficacy of vibration-controlled transient elastography (VCTE) with a controlled attenuation parameter (CAP) in a population of patients with non-alcoholic fatty liver disease (NAFLD)and to compare to US and different non-invasive indices.
Materials and methods. Single center NAFLD patients’ database of 2021–2023 years was retrospectively analysed. Data of VCTE evaluation with CAP (FibroScan 530® and FibroScan 630 Expert®) as well as liver US examination results and values of HSI, FLI, BAAT and NAFLD-LFS were extracted. AUROCs for all methods used were constructed and sensitivity and specificity analysis was performed.
Results. The data of 1081 patients were available for analysis (385 with steatosis, 274 with NASH, 422 without NAFLD as a control). Ultrasound examination in the diagnosis of liver steatosis compared to VCTE with CAP showed sensitivity and specificity of 94.6 and 63.7%, respectively. Diagnosis of liver steatosis using indices and scales showed sensitivity and specificity of HSI: 97.9 and 60.1% (AUROC 0.90), FLI: 92.5 and 85.3% (AUROC 0.93), BAAT: 76.6 and 73.5% (AUROC 0.82), NAFLD-LFS: 56.7 and 81.8% (AUROC 0.85).
Conclusion. The sensitivity of the US of the liver was consistent with previous studies, but the specificity was low. The HSI index had the best indicators of sensitivity and specificity in relation to the diagnosis of liver steatosis. Combination of liver US and HSI can be used in screening of liver steatosis, however, for the complete diagnosis better tools which can simultaneously evaluate liver steatosis and fibrosis should be used.
作者简介
Alexey Goncharov
Federal Research Center of Nutrition, Biotechnology and Food Safety
编辑信件的主要联系方式.
Email: thisalexis@gmail.com
ORCID iD: 0000-0002-8099-8602
аспирант отд-ния гастроэнтерологии, гепатологии и диетотерапии
俄罗斯联邦, MoscowArmida Sasunova
Federal Research Center of Nutrition, Biotechnology and Food Safety
Email: thisalexis@gmail.com
ORCID iD: 0000-0001-8896-5285
врач отд-ния гастроэнтерологии, гепатологии и диетотерапии
俄罗斯联邦, MoscowVladimir Pilipenko
Federal Research Center of Nutrition, Biotechnology and Food Safety
Email: thisalexis@gmail.com
ORCID iD: 0000-0001-5632-1880
канд. мед. наук, науч. сотр. отд-ния гастроэнтерологии и гепатологии
俄罗斯联邦, MoscowVasily Isakov
Federal Research Center of Nutrition, Biotechnology and Food Safety
Email: thisalexis@gmail.com
ORCID iD: 0000-0002-4417-8076
д-р мед. наук, проф., зав. отд-нием гастроэнтерологии, гепатологии и диетотерапии
俄罗斯联邦, Moscow参考
- Zoonosis ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-47. doi: 10.1097/HEP.0000000000000004
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
- Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021;S1542-3565(21):01280-5. doi: 10.1016/j.cgh.2021.12.002
- Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. doi: 10.21037/tgh.2019.09.08
- Ciardullo S, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(4):365-71. doi: 10.1097/MEG.0000000000002299
- Alon L, Corica B, Raparelli V, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938-46. doi: 10.1093/eurjpc/zwab212
- Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-88. doi: 10.1136/gutjnl-2021-324191
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121-40. doi: 10.1007/s00125-016-3902-y
- Nogami A, Yoneda M, Iwaki M, et al. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. Sci Rep. 2022;12(1):21925. doi: 10.1038/s41598-022-25843-6
- Лазебник Л.Б., Голованова Е.В., Туркина С.В., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1):4-52 [Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52 (in Russian)]. doi: 10.31146/1682-8658-ecg-185-1-4-52
- Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102 [Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Rossiiskii zhurnal gastroenterolpgii, gepatologii, koloproktologii. 2016;26(4):71-102 (in Russian)]. doi: 10.22416/1382-4376-2016-26-4-71-102
- Клинические рекомендации от 2021 г. «Хронический вирусный гепатит С». Режим доступа: https://medi.ru/klinicheskie-rekomendatsii/khronicheskij-virusnyj-gepatit-s-khvgs-u-vzroslykh_14028. Ссылка активна на 17.05.2023 [Clinical guidelines from 2021 “Chronic viral hepatitis C”. Available at: https://medi.ru/klinicheskie-rekomendatsii/khronicheskij-virusnyj-gepatit-s-khvgs-u-vzroslykh_14028. Accessed: 17.05.2023 (in Russian)].
- Jiang W, Huang S, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018;8(8):e021787. doi: 10.1136/bmjopen-2018-021787
- Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26(2):128-41. doi: 10.3350/cmh.2019.0001n
- Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825-35. doi: 10.1016/j.ultrasmedbio.2010.07.005
- Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. doi: 10.1186/s12876-019-0961-9
- Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-9. doi: 10.1016/j.jhep.2010.07.033
- Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-30. doi: 10.1016/j.jhep.2016.12.022
- Contreras D, González-Rocha A, Clark P, et al. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis. Ann Hepatol. 2023;28(1):100873. doi: 10.1016/j.aohep.2022.100873
- Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209-22. doi: 10.1111/apt.12963
- Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082-90. doi: 10.1002/hep.24452
- Leivas G, Maraschin CK, Blume CA, et al. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obes Res Clin Pract. 2021;15(5):461-5. doi: 10.1016/j.orcp.2021.09.002